Is HKEX ready to return to biotech business? InnoCare tests waters with hopes to fetch $257M in IPO
The Covid-19 outbreak may have forced InnoCare Pharma to postpone investor meetings ahead of its public debut on the Hong Kong Stock Exchange, but …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
